This contract expires in 71 days (Dec 31, 2026).
LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER - IGF::OT::IGF CONTRACEPTIVE CLINICAL TRIAL NETWORK - MALE SITES - CONTRACEPTIVE EFFICACY CLINICAL TRIALCONTRACT # HHSN275201300024I/HHSN27500007
Key Details
Description
IGF::OT::IGF CONTRACEPTIVE CLINICAL TRIAL NETWORK - MALE SITES - CONTRACEPTIVE EFFICACY CLINICAL TRIALCONTRACT # HHSN275201300024I/HHSN27500007
Context & Analysis
On Dec 15, 2025, Department of Health and Human Services obligated $11,791,957 to LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER for igf::ot::igf contraceptive clinical trial network - male sites - contraceptive efficacy clinical trialcontract # hhsn275201300024i/hhsn27500007. The award is classified under NAICS 541711 — RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY and issued as a cost no fee contract. Competition extent: full and open competition with 2 offers received. Performance is located in TORRANCE, CA. The contract is scheduled through Dec 31, 2026 — approximately 2 months remaining. This award is one of several similar procurements from Department of Health and Human Services under NAICS 541711 — related awards are listed below.
Market context
- Recompete outlook
- Ends Dec 31, 2026, in 2 months. Recompete signal as of Oct 12, 2026: 41/100, combining time to the end date, the incumbent's history with this agency, whether the award was competed, and its size.
- Competition
- Competed, with 2 offers. 100% of 20 awards in this market (Department of Health and Human Services awards in NAICS 541711 over the last 3 years) were competed; median 2 offers.
- Award size
- At $11.8M, this award is above the median of the 20 priced Department of Health and Human Services awards in NAICS 541711 over the last 3 years (median $4.3M).
- Largest vendors in this market
By obligations, Department of Health and Human Services awards in NAICS 541711 over the last 3 years.
- CERUS CORPORATION — 1 award, $185.5M
- MEDICINES COMPANY, THE — 1 award, $98.1M
- JANSSEN VACCINES & PREVENTION B.V. — 1 award, $48.9M
- DNAE GROUP HOLDINGS LIMITED — 1 award, $43.4M
- AVITA MEDICAL AMERICAS, LLC — 1 award, $40.8M
Computed from USAspending award data on Oct 12, 2026.
Contractor Information
Similar Awards
CERUS - DEVELOPMENT AND IMPLEMENTATION OF PATHOGEN REDUCTION TECHNOLOGY (PRT). IGF::OT::IGF
CERUS CORPORATION
$185.5M
THE MEDICINE COMPANY - ADVANCE THE DEVELOPMENT OF A PORTFOLIO OF ANTI-INFECTIVE PROGRAMS. IGF::OT::IGF
MEDICINES COMPANY, THE
$98.1M
IGF::OT::IGF
JANSSEN VACCINES & PREVENTION B.V.
$48.9M
IGF::OT::IGF - DNAE / PATHOGEN IDENTIFICATION FROM SPECIMEN, VIA CAPTURE, EXTRACTION AND SEQUENCING (PISCES)
DNAE GROUP HOLDINGS LIMITED
$43.4M
AUTOGRAFT-SPARING PRODUCTS FOR DEFINITIVE CARE OF BURN INJURIES
AVITA MEDICAL AMERICAS, LLC
$40.8M
Stay Updated
Get notified about new opportunities matching your interests.